Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: Analysis of amisulpride vs placebo in three clinical trials

Trajectories of treatment response to the psychopharmacological medication of the negative symptoms of schizophrenia demonstrate substantial heterogeneity. Approximately half of the patients included in our analysis showed little improvement, and the most severely ill at baseline responded the most.